Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 9 institutions in 1 country.
Norbert GrzaskoDepartment of Experimental Hematooncology, Medical University of Lublin, 20-400 Lublin, Poland.
Grzegorz CharlinskiDepartment of Hematology, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-228 Olsztyn, Poland.ORCID 0000-0002-0595-5864
Marta MorawskaDepartment of Experimental Hematooncology, Medical University of Lublin, 20-400 Lublin, Poland.ORCID 0000-0001-6836-2903
Pawel KicinskiDepartment of Experimental Hematooncology, Medical University of Lublin, 20-400 Lublin, Poland.ORCID 0000-0002-0142-4812
Anna Waszczuk-GajdaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Joanna Drozd-SokolowskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0002-4562-6264
Edyta SuboczDepartment of Internal Diseases and Hematology, Military Institute of Medicine, 04-141 Warsaw, Poland.ORCID 0000-0001-5225-3921
Danuta BlonskaDepartment of Hematology, Jan Biziel University Hospital No. 2, 85-168 Bydgoszcz, Poland.
Malgorzata RaznyDepartment of Hematology and Internal Diseases, Ludwik Rydygier Specialistic Hospital, 31-826 Cracow, Poland.
Agnieszka Druzd-SitekDepartment of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 00-001 Warsaw, Poland.
Jadwiga HolojdaDepartment of Hematology, Specialistic City Hospital, 59-220 Legnica, Poland.
Alina SwiderskaDepartment of Hematology, University Hospital in Zielona Gora, 65-046 Zielona Gora, Poland.
Lidia Usnarska-ZubkiewiczDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Anna MasternakDepartment of Hematology, Specialist Hospital in Opole, 45-372 Opole, Poland.
Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, 20-400 Lublin, Poland.ORCID 0000-0003-0135-4030
Medical University of Lublin · PLMedical University of Warsaw · PLJan Biziel University Hospital No. 2 in BydgoszczPublic Higher Medical Professional School in Opole · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity of Warmia and Mazury in Olsztyn · PLUniversity of Zielona Góra · PLWojskowy Instytut Medycyny Lotniczej · PLWroclaw Medical University · PL
Funding
Medical University of Lublin DS 464National Science Center UMO 2014/13/B/NZ6/02141
6 · The paper itself
Abstract
Multiple myeloma (MM) is an incurable disease and patients become refractory to the treatment in the course of the disease. Bendamustine-based regimens containing steroids and other agents are among the therapeutic options offered to MM patients. Here, we investigated the safety and the efficacy of bendamustine used in patients with refractory/relapsed MM (RRMM). The patients were treated with bendamustine and steroids (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. · full record | OpenQuestion